50 results about "Mesenchymal Progenitor Cell" patented technology

Pluri-differentiated human mesenchymal progenitor cells (MPCs) are isolated. A method isolates and purifies human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.

Methods for obtaining multipotent mesenchymal stem cells under serum-free conditions and methods for identifying multipotent mesenchymal progenitor cells are disclosed.

Methods for obtaining multipotent mesenchymal stem cells under serum-free conditions and methods for identifying multipotent mesenchymal progenitor cells are disclosed.

The present invention provides isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), which simultaneously express a plurality of genes that are markers for multiple cell lineages, wherein the multiple cell lineages comprise at least four different mesenchymal cell lineages (e.g., adipocyte, osteoblast, fibroblast, and muscle cell) and wherein each of the markers is specific for a single cell lineage. The present invention also method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.

There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.

The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Method and uses of the antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural / functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.

Provided herein are methods and kits for the isolation, processing and cryopreservation of mesenchymal cells from the Wharton's Jelly and vascular progenitor cells from umbilical cord tissue. Also provided are isolated mesenchymal cells or vascular progenitor cells obtained by the invention methods, and compositions thereof.

The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Method and uses of the antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural / functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.

Provided is a device comprising at least two layers, said at least two layers being at least partially overlapping (e.g., superposed) and contacting one another, wherein a first layer of said at least two layers comprises a non-biodegradable mesh, and wherein a second layer of the at least two layers comprises an electrospun element, and wherein the device is devoid of an extracellular matrix generated by mesenchymal progenitor cells, which are characterized by a reduced differentiation potential into an adipogenic lineage by at least about 50% as compared to differentiation potential of mesenchymal stem cells from an adult adipose source under identical assay conditions, and by an increased osteogenic differentiation potential by at least about 20% as compared to the osteogenic differentiation potential of adipose-derived MSCs under identical assays conditions.

A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.

Provided are methods of isolating an extracellular matrix from mesenchymal progenitor cells which are characterized by a reduced differentiation ability into an adipogenic lineage as compared to adipose-derived mesenchymal stem cells. Also provide isolated extracellular matrix and hybrid devices comprising electrospun elements and extracellular matrix which can be used for various tissue regeneration, repair and reconstruction surgeries.

A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) or demineralized tooth matrix (DTM), together with a site-responsive polymer, optionally further comprising bone morphogenetic proteins (BMP) and / or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint or a cranio-facial-maxillary bone, alveolar bone of maxilla and mandibula, spine, pelvis or long bones, or for construction or reconstruction of any extra skeletal bone, including for mechanical or biological support of artificial implants to the joint or of the joint or to the bone, for restoring and / or enhancing the formation of a new hyaline cartilage and subchondral bone structure. A kit is provided for performing transplantation of the composition into a joint, maxillary or mandibular alveolar bone or any bony structure of a mammal, including support of artificial implants.

Embodiments of the invention relate to methods, compositions and kits for the in vivo formation of vascularized new adipose tissue in a subject. Combination of endothelial progenitor cells (EPCs) and mesenchymal progenitor cells (MPCs) implanted in vivo in a subject work synergistically to promote the formation vascularized new adipose tissue.

The described invention provides a composition comprising mesenchymal progenitor cells (MPC) and processes for isolating or enriching the mesenchymal progenitor cells (MPCs) having a cell surface antigenic profile of CD34(−) / CD133(−) / CD45(−) / CD73(+) / CD90(+) / CD105(+) / CD44(−). The described invention also provides methods for differentiating the mesenchymal progenitor cells (MPCs) into various cell types.

A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.

There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.

A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and / or mineralized bone matrix (MBM) and optionally comprising bone morphogenetic protein / s (BMP) and / or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint and / or a cranio-facial maxillary bone, for restoring and / or enhancing the formation of a new hyaline cartilage and subchondral bone structure. The composition of the invention and method of treatment employing the same may be used for the treatment of hereditary or acquired bone disorders, hereditary or acquired cartilage disorders, malignant bone or cartilage disorders, metabolic bone diseases, bone infections, conditions involving bone or cartilage deformities and Paget's disease. The composition and method may further be used for the correction of complex fractures, bone replacement and formation of new bone in plastic or sexual surgery, for support of implants of joints, cranio-facial-maxillary bones, or other musculoskeletal implants, including artificial implants. The method of the invention may further be used for treating damaged joints or degenerative arthropathy associated with malformation and / or dysfunction of cartilage and / or subchondral bone. A kit is provided for performing transplantation into a joint or a cranio-facial-maxillary bone of a mammal of the composition of the invention.

Provided herein are compositions, methods, systems, and kits for wound healing. As shown herein, CCN2 / CTGF stimulated mesenchymal progenitor cells can form αSMA− fibroblasts. Further, TGFβ was shown to stimulate further differentiation of αSMA− fibroblasts to myofibroblasts associated with fibrosis. One aspect provides a composition including CCN2 / CTGF and a TGFβ inhibitor, a P38 inhibitor, or a tyrosine kinase inhibitor. Another aspect provides a method of treating tissue wounds with CCN2 / CTGF-containing compositions. Also provided are systems and kits for wound healing. Also provided are methods for forming αSMA− fibroblasts mesenchymal progenitor cells.

The invention relates to an application of an interstitial vascular cell and a mesenchymal progenitor cell in the prevention or treatment of rheumatoid arthritis. A medicinal composition containing the interstitial vascular cell and the mesenchymal progenitor cell from autologous fat is applied to a necessary object in order to substantially prevent or treat rheumatoid arthritis. The mesenchymal progenitor cell has a very high cytokine secretion ability, and can restore in-vivo body damages; and the interstitial vascular cell and the mesenchymal progenitor cell have chondroblasting and ossification ability. The invention also provides the medicinal composition containing the interstitial vascular cell and the mesenchymal progenitor cell, and a method for preventing and treating the rheumatoid arthritis.

The molecular mechanism underlying degenerative joint disease, also known as osteoarthritis (OA), is not fully understood. Disruption of mitogen inducible gene 6 (Mig-6) in mice by homologous recombination (KO mice) led to early onset OA as revealed by simultaneous enlargement and deformity of multiple joints, degradation of articular cartilage and the development of bony outgrowths or osteophytes within the joint space. The latter appeared to be derived from proliferation of mesenchymal progenitor cells followed by differentiation into chondrocytes. Because of the striking similarity to human OA, Mig-6 KO mice are a useful animal model for studying the mechanism of this disease and for testing new drugs or therapies for treating OA. These KO mice also developed epithelial hyperplasia, adenoma, and adenocarcinoma in organs such as lung, gallbladder, and bile duct. Mig-6 is therefore a tumor suppressor gene and is a candidate gene for the frequent Ip36 genetic alterations found in lung cancer. It can be used as a tumor biomarker as well as a target for cancer therapy. Mig-6 is located in human chromosome Ip36, a locus frequently associated with human lung cancer. Mig-6 is a negative regulator of EGF signaling, and like EGF, was induced by HGF / SF in human lung cancer cell lines. Frequently the receptors EGFR and Met were co-expressed, and Mig-6 was induced by both EGF and HGF / SF in a MAPK-dependent fashion. Not all tumor lines express Mig-6 in response to either EGF or HGF / SF. In these cases, missense and nonsense mutations in the Mig-6 coding region were found, as was evidence for Mig-6 transcriptional silencing.

The invention relates to application of stromal vascular fraction cells and mesenchymal progenitor cells to the prevention or treatment of osteoarthritis. Specifically, remarkable prevention or treatment effects on osteoarthritis are achieved by applying a medicinal composition containing the stromal vascular fraction cells and the mesenchymal progenitor cells from autologous fat to an object with requirements. The mesenchymal progenitor cells have high cytokine secretion capability and the effect of repairing damage to organisms in a body. The stromal vascular fraction cells and the mesenchymal progenitor cells have chondrogenic differentiation and bone formation capability. The invention also provides the medicinal composition containing the stromal vascular fraction cells and the mesenchymal progenitor cells and a method for preventing and treating osteoarthritis.

The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine.

There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.

The invention relates to application of allogenic stromal vascular fraction cells and allogenic mesenchymal progenitor cells in prevention or treatment of rheumatoid arthritis. Specifically speaking, the pharmaceutical composition containing allogenic stromal vascular fraction cells and allogenic mesenchymal progenitor cells derived from allogenic fat is applied to an object in need, exerts a substantial prevention or treatment effect on rheumatoid arthritis and has good security and no rejection reaction. The invention further provides the pharmaceutical composition containing allogenic stromal vascular fraction cells and allogenic mesenchymal progenitor cells and a method for preventing and treating rheumatoid arthritis.

There is provided an isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), a method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures, and characterization of and uses, particularly therapeutic uses for such cells. Specifically, there is provided isolated MPCs which can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.

Described herein is a mesenchymal human progenitor (hBS-MP) cell population derived from human blastocyst-derived stem (hBS) cells and a method to obtain the progenitor cell population in which is eliminated the need of co-culture steps, cell sorting, manual selection, and transfections. Also, the use of the hBS-MP cells in drug discovery and specifically for toxicity testings as well as for therapeutic use is made possible.

The invention relates to a use of a fat mesenchymal progenitor cell and platelet-rich blood plasma composition in prevention or treatment of hepatitis, particularly, relates to a use of the fat mesenchymal progenitor cell and platelet-rich blood plasma composition in preparation of a drug composition for treatment of hepatitis B. After a required object is administered with the drug composition, indexes such as hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody and the like can be improved, hepatitis virus DNA can be significant reduced, and ALT can be reduced so as to promote restoration of liver functions.